Therapeutic potential of curcumin in non-alcoholic steatohepatitis

Nutrition Research Reviews

Volumn 18, Issue 2, 2005, Pages 212-221

  Shapiro, Haim ^a   Bruck, Rafael ^b,c  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Curcumin; Diferuloylmethane; Fibrosis; Oxidative stress; Steatohepatitis; Steatosis

Indexed keywords

CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYPHENOL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; FIBROSIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; STELLATE CELL;

ANIMALIA; RODENTIA;

EID: 31144478126     PISSN: 09544224     EISSN: None     Source Type: Journal    
DOI: 10.1079/NRR2005106     Document Type: Review

References (97)

1. Abe Y, Hashimoto S & Horie T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacological Research 39, 41-47.
2. Aggarwal BB, Kumar A & Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Research 23, 363-398.
3. Albanis E, Safadi R & Friedman SL (2003) Treatment of hepatic fibrosis: almost there. Current Gastroenterology Reports 5, 48-56.
4. Angulo P (2002) Nonalcoholic fatty liver disease. New England Journal of Medicine 346, 1221-1231.
5. Asai A & Miyazawa T (2001) Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. Journal of Nutrition 131, 2932-2935.
6. Babu PS & Srinivasan K (1997) Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats. Molecular and Cellular Biochemistry 166, 169-175.
7. Balla J, Vercellotti GM, Nath K, Yachie A, Nagy E, Eaton JW & Balla G (2003) Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrology Dialysis Transplantation 18, 8-12.
8. Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, Alam J & Motterlini R (2003) Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochemical Journal 371, 887-895.
9. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Muller M, Mackman N, Ziegler R & Nawroth PP (1997) The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thrombosis and Haemostasis 77, 772-782.
10. Browning JD & Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation 114, 147-152.
11. Chan MM (1995) Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochemical Pharmacology 49, 1551-1556.
12. Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST & Ganguli M (2001) Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology 57, 985-989.
13. Chen A & Xu J (2005) Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates the suppression of the gene expression of cyclin D1 and EGFR. American Journal of Physiology 288, G447-G456.
14. Chen YR & Tan TH (1998) Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17, 173-178.
15. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Research 21, 2895-2900.
16. Choudhury J & Sanyal AJ (2004) Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clinics in Liver Disease 8, 575-594.
17. Chuang SE, Cheng AL, Lin JK & Kuo ML (2000a) Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food and Chemical Toxicology 38, 991-995.
18. Chuang SE, Kuo ML, Hsu CH, Chen CR, Lin JK, Lai GM, Hsieh CY & Cheng AL (2000b) Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis 21, 331-335.
19. Chun KS, Keum YS, Han SS, Song YS, Kim SH & Surh YJ (2003) Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis 24, 1515-1524.
20. den Boer M, Voshol PJ, Kuipers F, Havekes LM & Romijn JA (2004) Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arteriosclerosis, Thrombosis and Vascular Biology 24, 644-649.
21. Diehl AM (2004) Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clinics in Liver Disease 8, 619-638.
22. Friedman SL (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. Journal of Biological Chemistry 275, 2247-2250.
23. Gaedeke J, Noble NA & Border WA (2004) Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells. Kidney International 66, 112-120.
24. Gao X, Kuo J, Jiang H, Deeb D, Liu Y, Divine G, Chapman RA, Dulchavsky SA & Gautam SC (2004) Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. Biochemical Pharmacology 68, 51-61.
25. Ghoneim AI, Abdel-Naim AB, Khalifa AE & El-Denshary ES (2002) Protective effects of curcumin against ischaemia/reperfusion insult in rat forebrain. Pharmacological Research 46, 273-279.
26. Gukovsky I, Reyes CN, Vaquera EC, Gukovskaya AS & Pandol SJ (2003) Curcumin ameliorates ethanol and nonethanol experimental pancreatitis. American Journal of Physiology 284, G85-G95.
27. Heyninck K, Wullaert A & Beyaert R (2003) Nuclear factor-kappa B plays a central role in tumour necrosis factor-mediated liver disease. Biochemical Pharmacology 66, 1409-1415.
28. Iqbal M, Sharma SD, Okazaki Y, Fujisawa M & Okada S (2003) Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacology and Toxicology 92, 33-38.
29. Ishida J, Ohtsu H, Tachibana Y, Nakanishi Y, Bastow KF, Nagai M, Wang HK, Itokawa H & Lee KH (2002) Antitumor agents. Part 214: synthesis and evaluation of curcumin analogues as cytotoxic agents. Bioorganic Medical Chemistry 10, 3481-3487.
30. Joe B & Lokesh BR (1994) Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochimica et Biophysica Acta 1224, 255-263.
31. Joe B, Vijaykumar M & Lokesh BR (2004) Biological properties of curcumin-cellular and molecular mechanisms of action. Critical Review of Food Science and Nutrition 44, 97-111.
32. Kang HC, Nan JX, Park PH, Kim JY, Lee SH, Woo SW, Zhao YZ, Park EJ & Sohn DH (2002) Curcumin inhibits collagen synthesis and hepatic stellate cell activation in-vivo and in-vitro. Journal of Pharmacy and Pharmacology 54, 119-126.
33. Kempaiah RK & Srinivasan K (2004) Influence of dietary curcumin, capsaicin and garlic on the antioxidant status of red blood cells and the liver in high-fat-fed rats. Annals of Nutrition Metabolism 48, 314-320.
34. Kumar A, Dhawan S, Hardegen NJ & Aggarwal BB (1998) Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappa B activation. Biochemical Pharmacology 55, 775-783.
35. Leclercq IA, Farrell GC, Sempoux C, Pena AD & Horsmans Y (2004) Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. Journal of Hepatology 41, 926-934.
36. Lee JJ, Huang WT, Shao DZ, Liao JF & Lin MT (2003) Blocking NF-kappaB activation may be an effective strategy in the fever therapy. Japanese Journal of Physiology 53, 367-375.
37. Leu TH & Maa MC (2002) The molecular mechanisms for the antitumorigenic effect of curcumin. Current Medicinal Chemistry - Anti-Cancer Agents 2, 357-370.
38. Li L, Grenard P, Nhieu JT, Julien B, Mailat A, Habib A & Lotersztajn (2003) Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology 125, 460-469.
39. Lim GP, Chu T, Yang F, Beech W, Frautschy SA & Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Journal of Neuroscience 21, 8370-8377.
40. Lukita-Atmadja W, Ito Y, Baker GL & McCuskey RS (2002) Effect of curcuminoids as anti-inflammatory agents on the hepatic microvascular response to endotoxin. Shock 17, 399-403.
41. Madan B & Ghosh B (2003) Diferuloylmethane inhibits neutrophil infiltration and improves survival of mice in high-dose endotoxin shock. Shock 19, 91-96.
42. Manach C, Scalbert A, Morand C, Remesy C & Jimenez L (2004) Polyphenols: food sources and bioavailability. American Journal of Clinical Nutrition 79, 727-747.
43. Medina J, Fernandez-Salazar LI, Garcia-Buey L & Moreno-Otero R (2004) Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 27, 2057-2066.
44. Miquel J, Bernd A, Sempere JM, Diaz-Alperi J & Ramirez A (2002) The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Archives of Gerontology and Geriatrics 34, 37-46.
45. Mishra B, Priyadarsini KI, Bhide MK, Kadam RM & Mohan H (2004) Reactions of superoxide radicals with curcumin: probable mechanisms by optical spectroscopy and EPR. Free Radical Research 38, 355-362.
46. Morikawa T, Matsuda H, Ninomiya K & Yoshikawa M (2002) Medicinal foodstuffs. XXIX. Potent protective effects of sesquiterpenes and curcumin from Zedoariae Rhizoma on liver injury induced by D-galactosamine/lipopolysaccharide or tumor necrosis factor-alpha. Biological and Pharmaceutical Bulletin 25, 627-631.
47. Motterlini R, Foresti R, Bassi R & Green CJ (2000) Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radical Biology and Medicine 28, 1303-1312.
48. Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, Kajimoto Y, Matsuhisa M, Yamasaki Y & Hori M (2004) Modulation of the JNK pathway in liver affects insulin resistance status. Journal of Biological Chemistry 279, 45803-45809.
49. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P & Dannenberg AJ (2003) Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. American Journal of Physiology 284, G321-G327.
50. National Institutes of Health (2004a) Curcumin in patients with mild to moderate Alzheimer's disease. Accessed March 2005. http://clinicaltrials.gov/ct/ show/NCT00099710?order=1.
51. National Institutes of Health (2004b) Trial of curcumin in advanced pancreatic cancer. Accessed March 2005. http:// clinicaltrials.gov/ct/show/ NCT00094445?order=2.
52. Neuschwander-Tetri BA & Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37, 1202-1219.
53. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K & Kitahara M (2005) Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-A(y) mice. Journal of Agricultural and Food Chemistry 53, 959-963.
54. Oetari S, Sudibyo M, Commandeur JN, Samhoedi R & Vermeulen NP (1996) Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. Biochemical Pharmacology 51, 39-45.
55. Ogihara T, Asano T, Katagiri H, Sakoda H, Anai M, Shojima N, Ono H, Fujishiro M, Kushiyama A, Fukushima Y, Kikuchi M, Noguchi N, et al. (2004) Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase. Diabetologia 47, 794-805.
56. Park EJ, Jeon CH, Ko G, Kim J & Sohn DH (2000) Protective effect of curcumin in rat liver injury induced by carbon tetrachloride. Journal of Pharmacy and Pharmacology 52, 437-440.
57. Park SD, Jung JH, Lee HW, Kwon YM, Chung KH, Kim MG & Kim CH (2005) Zedoariae rhizoma and curcumin inhibits platelet-derived growth factor-induced proliferation of human hepatic myofibroblasts. International Immunophamacology 5, 555-569.
58. Pendurthi UR, Williams JT & Rao LV (1997) Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. Arteriosclerosis, Thrombosis and Vascular Biology 17, 3406-3413.
59. Philip S & Kundu GC (2003) Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. Journal of Biological Chemistry 278, 14487-14497.
60. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S & Howells L (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18, 6013-6020.
61. Punithavathi D, Venkatesan N & Babu M (2003) Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats. British Journal of Pharmacology 139, 1342-1450.
62. Quiles JL, Aguilera C, Mesa MD, Ramirez-Tortosa MC, Baro L & Gil A (1998) An ethanolic-aqueous extract of Curcuma longa decreases the susceptibility of liver microsomes and mitochondria to lipid peroxidation in atherosclerotic rabbits. Biofactors 8, 51-57.
63. Quiles JL, Mesa MD, Ramirez-Tortosa CL, Aguilera CM, Battino M, Gil A & Ramirez-Tortosa MC (2002) Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits. Arteriosclerosis, Thrombosis and Vascular Biology 22, 1225-1231.
64. Rasyid A & Lelo A (1999) The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Alimentary Pharmacology and Therapeutics 13, 245-249.
65. Rasyid A, Rahman AR, Jaalam K & Lelo A (2002) Effect of different curcumin dosages on human gall bladder. Asia Pacific Journal of Clinical Nutrition 11, 314-318.
66. Reddy AC & Lokesh BR (1994) Effect of dietary turmeric (Curcuma longa) on iron-induced lipid peroxidation in the rat liver. Food and Chemical Toxicology 32, 279-283.
67. Reddy AC & Lokesh BR (1996) Effect of curcumin and eugenol on iron-induced hepatic toxicity in rats. Toxicology 107, 39-45.
68. Rinella ME & Green RM (2004) The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. Journal of Hepatology 40, 47-51.
69. Robinson TP, Ehlers T, Hubbard RB IV, Bai X, Arbiser JL, Goldsmith DJ & Bowen JP (2003) Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. Bioorganic Medical Chemistry Letter 13, 115-117.
70. Rukkumani R, Aruna K, Varma PS & Menon VP (2004a) Curcumin influences hepatic expression patterns of matrix metalloproteinases in liver toxicity. Italian Journal of Biochemistry 43, 61-66.
71. Rukkumani R, Aruna K, Varma PS, Rajasekaran KN & Menon VP (2004b) Comparative effects of curcumin and an analog of curcumin on alcohol and PUFA induced oxidative stress. Journal of Pharmacy and Pharmaceutical Sciences 7, 274-283.
72. Rukkumani R, Sri Balasubashini M & Menon VP (2003) Protective effects of curcumin and photo-irradiated curcumin on circulatory lipids and lipid peroxidation products in alcohol and polyunsaturated fatty acid-induced toxicity. Phytotherapy Research 17, 925-929.
73. Rukkumani R, Sri Balasubashini M, Vishwanathan P & Menon VP (2002) Comparative effects of curcumin and photo-irradiated curcumin on alcohol- and polyunsaturated fatty acid-induced hyperlipidemia. Pharmacogical Research 46, 257-264.
74. Sahai A, Malladi P, Melin-Aldana H, Green RM & Whitington PF (2004) Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. American Journal of Physiology 287, G264-G273.
75. Sass DA, Chang P & Chopra KB (2005) Nonalcoholic fatty liver disease: a clinical review. Digestive Diseases and Science 50, 171-180.
76. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC & Sarin SK (2004) Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. American Journal of Gastroenterology 99, 1946-1952.
77. Scapagnini G, Foresti R, Calabrese V, Green CJ & Motterlini R (2002) Caffeic acid phenethyl ester and curcumin: a novel class of heme oxygenase-1 inducers. Molecular Pharmacology 61, 554-561.
78. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, et al. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clinical Cancer Research 10, 6847-6854.
79. Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, Leuratti C, Manson MM, Marnett LJ, Steward WP & Gescher A (2001a) Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clinical Cancer Research 7, 1452-1458.
80. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ & Steward WP (2001b) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clinical Cancer Research 7, 1894-1900.
81. Shishodia S, Potdar P, Gairola CG & Aggarwal BB (2003) Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 24, 1269-1279.
82. Shoskes DA (1998) Effect of bioflavonoids quercetin and curcumin on ischemic renal injury: a new class of renoprotective agents. Transplantation 66, 147-152.
83. Shukla Y & Arora A (2003) Suppression of altered hepatic foci development by curcumin in Wistar rats. Nutrition and Cancer 45, 53-59.
84. Singh S & Aggarwal BB (1995) Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). Journal of Biological Chemistry 270, 24995-25000.
85. Stravitz RT & Sanyal AJ (2003) Drug-induced steatohepatitis. Clinics in Liver Disease 7, 435-451.
86. Syng-Ai C, Kumari AL & Khar A (2004) Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Molecular Cancer Therapeutics 3, 1101-1108.
87. Venkatesan N (1998) Curcumin attenuation of acute adriamycin myocardial toxicity in rats. British Journal of Pharmacology 124, 425-427.
88. Venkatesan N, Punithavathi D & Arumugam V (2000) Curcumin prevents adriamycin nephrotoxicity in rats. British Journal of Pharmacology 129, 231-234.
89. Venkatesan P & Rao MN (2000) Structure-activity relationships for the inhibition of lipid peroxidation and the scavenging of free radicals by synthetic symmetrical curcumin analogues. Journal of Pharmacy and Pharmacology 52, 1123-1128.
90. Watanabe S & Fukui T (2000) Suppressive effect of curcumin on trichloroethylene-induced oxidative stress. Journal of Nutritional Science and Vitaminology (Tokyo) 46, 230-234.
91. World Health Organization (2000) Evaluation of Certain Food Additives: 51st Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report no. 891. Geneva: WHO.
92. Xu J, Fu Y & Chen A (2003) Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. American Journal of Physiology 285, G20-G30.
93. Xu YX, Pindolia KR, Janakiraman N, Chapman RA & Gautam SC (1997-98) Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopathology and Molecular Hematology 11, 49-62.
94. Yao QH, Wang DQ, Cui CC, Yuan ZY, Chen SB, Yao XW, Wang JK & Lian JF (2004) Curcumin ameliorates left ventricular function in rabbits with pressure overload: inhibition of the remodeling of the left ventricular collagen network associated with suppression of myocardial tumor necrosis factor-alpha and matrix metalloproteinase-2 expression. Biological and Pharmaceutical Bulletin 27, 198-202.
95. Yeon JE, Choi KM, Baik SH, Kim KO, Lim HJ, Park KH, Kim JY, Park JJ, Kim JS, Bak YT, Byun KS & Lee CH (2004) Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 19, 799-804.
96. Zheng S & Chen A (2004) Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochemical Journal 384, 49-57.
97. Zuckerbraun BS & Billiar TR (2003) Heme oxygenase-1: a cellular Hercules. Hepatology 37, 742-743.